checkpoint inhibitors

In June 2025, the Food and Drug Administration rolled out Elsa, an agency-wide generative AI assistant that officials say is already helping to speed the review of new drugs and devices and shrink weeks of paperwork into minutes. It is a vision that could reshape how lifesaving therapies reach patients, but Elsa’s first six months…

A new study, published in the Journal of Clinical Investigation, suggests that identifying distinct immune “signatures” in patients may help oncologists predict and prevent adverse events associated with immunotherapy. This observational study, reportedly the largest of its kind, prospectively enrolled 111 patients with solid tumors receiving immune checkpoint inhibitor (ICI) therapy at Johns Hopkins. Researchers…

With some of the recently developed drugs showing unprecedented response rates and consistent improvement in overall survival in some indications, we face the dawn of a new era in anticancer research. New therapeutic targets, novel classes of products, booming and competing pipelines, innovative statistical methods, and a changing regulatory environment are all features of this…